Previous 10 | Next 10 |
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing ...
2023-09-11 16:12:13 ET More on Crinetics Pharmaceuticals Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals Historical earnings data for Crinetics Pharmaceuticals Financial information for Crinetics Pharmaceuticals Crinetics Pharmaceuticals: Cre...
2023-09-11 12:58:57 ET Gainers: Super League Gaming ( SLE ) +182% . Crinetics Pharmaceuticals ( CRNX ) +66% . Aurora Cannabis ( ACB ) +55% . Canopy Growth Corporation ( CGC ) +46% . Avantax ( AVTA ) +28% . Clever Leaves Holdi...
2023-09-11 12:57:53 ET Shares of Crinetics Pharmaceuticals (NASDAQ: CRNX) were up more than 67% as of 12:30 p.m. ET on Monday after the company posted positive phase 3 trial results for one of its therapies. The healthcare stock is up more than 28% for the year. Crinetics fo...
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is one of today's top gainers. The company's shares are currently up 67.89% on the day to $26.81. Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic...
2023-09-11 06:53:28 ET More on Crinetics Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals Historical earnings data for Crinetics Pharmaceuticals Financial information for Crinetics Pharmaceuticals Crinetics Pharmaceuticals: Creating Next-Gener...
2023-09-11 05:18:10 ET More on Crinetics Pharmaceuticals, Tesla, etc. Tesla: When There's A Dividend, Count Me In Tesla: Overvalued Car Company - Likely To Face Further Margin Deterioration Buy Rating For Tesla Ahead Of An Impending Rally Why I Decided To Sho...
83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After Switching from Injected Depot Standard of Care Mean Acromegaly Symptom Diary S...
2023-08-31 09:42:53 ET More on Crinetics Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO Crinetics says FDA didn’t clear Phase 2 study request for hyperinsulinis...
2023-08-28 18:07:28 ET Summary Crinetics Pharmaceuticals, Inc. is my latest long position. The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused by excess levels of growth hormone, and current...
News, Short Squeeze, Breakout and More Instantly...
Crinetics Pharmaceuticals Inc. Company Name:
CRNX Stock Symbol:
NASDAQ Market:
Crinetics Pharmaceuticals Inc. Website:
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its com...
2024-06-25 22:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...